Clinical trial
Fenretinide in Treating Patients With Recurrent or Metastatic Ovarian Epithelial…
NCT00026091 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00026091 |
|---|---|
| Title | Fenretinide in Treating Patients With Recurrent or Metastatic Ovarian Epithelial or Primary Peritoneal Cancer |
| Official title | Phase II Trial of Fenretinide (NSC 374551) in Recurrent Ovarian Cancer and Primary Peritoneal Carcinoma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Recurrent Ovarian Epithelial Cancer, Recurrent Primary Peritoneal Cavity Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Primary Peritoneal Cavity Cancer |
| Intervention type | Drug, Other |
| Interventions | fenretinide, laboratory biomarker analysis, pharmacological study |
| Enrollment | 40 |
| Start date | Sep 1, 2001 |
| Primary completion | Mar 1, 2004 |
| First posted | Jan 27, 2003 |
| Last update posted | Mar 25, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: